Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Short term Debt: 2023-2024

Historic Short term Debt for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $4.5 million.

  • BioLineRx's Short term Debt fell 57.97% to $4.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.5 million, marking a year-over-year decrease of 57.97%. This contributed to the annual value of $4.5 million for FY2024, which is 42.42% up from last year.
  • Per BioLineRx's latest filing, its Short term Debt stood at $4.5 million for FY2024, which was up 42.42% from $3.1 million recorded in FY2023.
  • BioLineRx's 5-year Short term Debt high stood at $4.5 million for FY2024, and its period low was $3.1 million during FY2023.
  • In the last 2 years, BioLineRx's Short term Debt had a median value of $3.8 million in 2023 and averaged $3.8 million.
  • Data for BioLineRx's Short term Debt shows a peak YoY soared of 42.42% (in 2024) over the last 5 years.
  • Over the past 2 years, BioLineRx's Short term Debt (Yearly) stood at $3.1 million in 2023, then skyrocketed by 42.42% to $4.5 million in 2024.